2025
Association of stress-induced autonomic dysfunction with heart failure in individuals with stable coronary artery disease
Wang M, Liu C, Shah A, Ko Y, Lampert R, Sun Y, Moazzami K, Garcia M, Almuwaqqat Z, Najarro G, Sullivan S, Raggi P, Bremner J, Quyyumi A, Vaccarino V, Morris A, Shah A. Association of stress-induced autonomic dysfunction with heart failure in individuals with stable coronary artery disease. IJC Heart & Vasculature 2025, 59: 101694. DOI: 10.1016/j.ijcha.2025.101694.Peer-Reviewed Original ResearchStable coronary artery diseaseResting heart rate variabilityCoronary artery diseaseLow-frequency heart rate variabilityHF riskMental stress challengeHeart rate variabilityHeart failureIncreased risk of incidentAcute HFAutonomic dysfunctionRisk of incidentBackground Heart failureAssociated with higher riskArtery diseaseCox proportional hazards modelsStrong effect sizesDiagnosis of HFIncreased HF riskProportional hazards modelMedian follow-upInpatient settingStandard deviation decreaseHRV changesEvaluate heart rate variabilityCarcinogenic Industrial Air Emissions and Lung Cancer Risk in a Cohort of 440,000 Americans.
Madrigal J, Fisher J, Pruitt C, Liao L, Graubard B, Ward M, Silverman D, Jones R. Carcinogenic Industrial Air Emissions and Lung Cancer Risk in a Cohort of 440,000 Americans. American Journal Of Respiratory And Critical Care Medicine 2025, 211: 1241-1252. PMID: 40315142, DOI: 10.1164/rccm.202409-1738oc.Peer-Reviewed Original ResearchConceptsLung cancer riskCancer riskAssociated with riskNIH-AARP DietEvaluate lung cancer riskLung carcinogensAssociated with lung cancerCox proportional hazards modelsNIH-AARPHealth StudyProportional hazards modelSquamous cell carcinomaStrong associationsAssociated with benzeneHazards modelIndustrial air emissionsEnrollment residenceCell carcinomaOverall riskLung cancer developmentSmokingAssociationRiskHistological subtypesLung cancerAPOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban
Clocchiatti-Tuozzo S, Rivier C, Renedo D, Huo S, de Havenon A, Hawkes M, Gilmore E, Schwamm L, Sheth K, Gill T, Falcone G. APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban. JAMA Neurology 2025, 82 PMID: 40549373, PMCID: PMC12186128, DOI: 10.1001/jamaneurol.2025.0182.Peer-Reviewed Original ResearchRisk of intracranial hemorrhagePopulation-based studyYears of follow-up dataApo E4Cox proportional hazards modelsAPOE e4 alleleIntracranial hemorrhageRisk prediction scoreCerebral amyloid angiopathyClinical decision-makingProportional hazards modelAtrial fibrillationIncreased risk of ICHMultivariate Cox proportional hazards modelMain OutcomesIncident intracranial hemorrhageEuropean ancestryCohort studyInclusion criteriaHistory of ischemic strokeAmyloid angiopathyE4 variantHazards modelIncreased riskE4 allele308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MICKELSON M, MCCOY R. 308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-308-or.Peer-Reviewed Original ResearchDipeptidyl peptidase-4 inhibitorsIncident cancer riskSodium-glucose cotransporter 2 inhibitorsIncident cancerGLP-1RACancer riskHigher risk of incident cancerType 2 diabetesRisk of incident cancerHigh riskReceptor agonistsMedicare fee-for-serviceFemale breast cancerFee-for-serviceGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsPropensity score inverse probabilityTarget trial emulationModerate CVD riskCox proportional hazards modelsOptumLabs Data WarehousePeptidase-4 inhibitorsIncidence of melanomaAdverse cardiovascular events779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MARON B, MCCOY R. 779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk. Diabetes 2025, 74 DOI: 10.2337/db25-779-p.Peer-Reviewed Original ResearchModerate CVD riskCVD riskType 2 diabetesCardiovascular diseaseAssociated with lower hazardRisk of cardiovascular outcomesCardiovascular disease outcomesCox proportional hazards modelsCardiovascular outcomesGlucagon-like peptide-1 receptor agonistsModerate cardiovascular riskCardiovascular risk reductionDigestive and Kidney DiseasesPeptide-1 receptor agonistsPropensity score inverse probabilityProportional hazards modelHazard of deathDepartment visitsNational Institute of DiabetesHazard of MACETrial emulationMedicare AdvantageMedicare plansComparative riskHazards modelSurvival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status.
Ayoade O, Canavan M, Caturegli G, Zolfaghari E, Resio B, Woodard G, Boffa D. Survival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e24041.Peer-Reviewed Original ResearchCancer patient survivalPatient survivalTumor behaviorCOVID-19 infectionCancer typesCharlson-Deyo scoreNational Cancer DatabaseSurvival of patientsKaplan Meier analysisCox proportional hazards modelsStage IV cancerAssociated with lower mortality riskProportional hazards modelCOVID-positive patientsMeier analysisCancer DatabaseLower mortality riskPositive patientsTreatment modalitiesDeyo scoreIV cancerImmune modulationImmunological consequencesCancer patientsYear mortalityAssociation between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden.
Palencia P, Zhao X, Kandala K, Smani S, Sivanesan N, Cavallo J, Leapman M. Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17123.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate radiation therapyMetastatic prostate cancerOverall survivalRadiation therapyProstate cancerM1c diseaseTreatment modalitiesRT to ADTTreated with androgen deprivation therapyAssociated with improved overall survivalHormone-sensitive prostate cancerAssociated with poor overall survivalPrimary local therapyExternal beam radiotherapyGleason grade groupCompare overall survivalNational Cancer DatabaseProstate cancer metastasisLog-rank testDisease burdenKaplan-Meier curvesCox proportional hazards modelsLow disease burdenAssociation between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis
Theprungsirikul P, Wang R, Ahmad I, Neparidze N, Ma X, Chang S, Wang S. Association between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis. Clinical Lymphoma Myeloma & Leukemia 2025 DOI: 10.1016/j.clml.2025.06.016.Peer-Reviewed Original ResearchSmoldering multiple myelomaSmoldering multiple myeloma patientsMultiple myelomaPatient demographicsProgression to multiple myelomaSymptomatic multiple myelomaDevelopment of hypercalcemiaCox proportional hazards modelsRisk stratification modelConfidence intervalsNon-cancer controlsEstimate hazard ratiosProportional hazards modelNon-cancer patientsSymptomatic MMRandom sample of Medicare beneficiariesSMM patientsRenal failureAnalyzed SurveillanceSEER-MedicareNatural history modelHazard ratioBone diseasePatientsSample of Medicare beneficiariesChitinase 3-like-1 (CHI3L1): A potential prognostic biomarker for immunotherapy (IO) in non-small cell lung cancer (NSCLC).
Khan H, Gandhi N, Kamle S, Ma B, Lee C, Xiu J, Vanderwalde A, Lopes G, Halmos B, Azzoli C, Elias J. Chitinase 3-like-1 (CHI3L1): A potential prognostic biomarker for immunotherapy (IO) in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e20622.Peer-Reviewed Original ResearchNon-small cell lung cancerPD-L1Immune checkpointsCHI3L1 expressionDriver alterationsHazard ratioAnti-tumor immune responseExpression of immune checkpointsNon-small cell lung cancer specimensCaris Life SciencesInducing PD-1Chitinase 3-like 1Immune checkpoint inhibitorsPD-L1 expressionImmune checkpoint expressionCell lung cancerEnhanced expressionImmune cell infiltrationLog-rank testEffects of CHI3L1Expression of CHI3L1Cox proportional hazards modelsKaplan-Meier estimatesProportional hazards modelStatistically significant associationInhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US Cohort Study
Thornburg C, van den Berg H, Chandler M, Malec L, Manuel M, O’Neill C, Recht M, Taggart E, Carpenter S, group A, Knoll C, Malec L, Wang M, Guerrera M, Tarango C, Sidonio R, Rodriguez N, Friedman K, Shapiro A, Yaish H, Carpenter S, Janbain M, Grabowski E, Pruthi R, Haley K, Thornburg C, Ahuja S, Simpson M, Reiss U, Lucas T, Balasa V, Wheeler A. Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US Cohort Study. Blood Vessels Thrombosis & Hemostasis 2025, 100082. DOI: 10.1016/j.bvth.2025.100082.Peer-Reviewed Original ResearchClotting factor concentratesSevere hemophilia AHemophilia AInhibitor developmentExposure daysCohort studyAssociated with inhibitor developmentLow-titer inhibitorsReduce inhibitor developmentHigh-titer inhibitorsCox proportional hazards modelsEvaluate risk factorsClinically significant inhibitorUS cohort studyProportional hazards modelCongenital hemophiliaUntreated patientsSevere HAClinical characteristicsPrevent bleedingNeutralizing antibodiesModerate haemophiliaNonsense variantFactor concentrationsRisk factorsMolecular markers associated with survival in PD-L1– high non-small cell lung cancer treated with first-line immunotherapy versus chemoimmunotherapy.
Lee V, Oh P, Rybkin A, Patel A, Kim S, Park H. Molecular markers associated with survival in PD-L1– high non-small cell lung cancer treated with first-line immunotherapy versus chemoimmunotherapy. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e20607.Peer-Reviewed Original ResearchNon-small cell lung cancerFirst-line immunotherapyTreated with first-line immunotherapyPD-L1 expressionCell lung cancerPD-L1Advanced non-small cell lung cancerLung cancerPresence of co-mutationsAssociated with improved OSAssociated with worse OSBaseline ECOG performance statusMultivariate Cox proportional hazards modelSingle-agent immunotherapyUS cancer clinicsAdvanced NSCLC patientsECOG performance statusOptimal treatment strategyCox proportional hazards modelsAssociated with survivalClinico-genomic databasePresence of brainProportional hazards modelTreated with IMetastatic sitesMolecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer (aBC).
Bou Farhat E, Nassar A, Abushukair H, Alchoueiry M, Salem S, Machaalani M, Henske E, Choueiri T, Rakaee M, Adib E, Naqash A, Jansen C, Wang X, Challa P, Rodig S, Tarantino P, Partridge A, Tolaney S, Winer E, Kwiatkowski D. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer (aBC). Journal Of Clinical Oncology 2025, 43: 1040-1040. DOI: 10.1200/jco.2025.43.16_suppl.1040.Peer-Reviewed Original ResearchTime to next treatmentAdvanced breast cancerTumor micro-environmentT-DXdHER2-lowOverall survivalHER2 statusERBB2 amplificationHER2-0Shorter time to next treatmentPTEN-mutatedFirst-line systemic therapyMultivariate Cox proportional hazards modelHER2 3+Cox proportional hazards modelsRefine treatment strategiesPredictive of outcomeTargeted tumor sequencingProportional hazards modelImpact of molecular markersHER2 3Trastuzumab deruxtecanHER2-positiveHER2 immunohistochemistrySystemic therapyClinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population.
Argulian A, Van Hyfte G, Baldwin E, Kulshrestha A, Lucas N, Wilk J, Wu K, Yuan M, Fazilov G, Fitzgerald L, Hapanowicz O, Osorio M, Cuevas J, Wawrzyniak A, Acuna-Villaorduna A, Zamarin D, Feng D, Galsky M, Marron T, Doroshow D. Clinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population. Journal Of Clinical Oncology 2025, 43: e13514-e13514. DOI: 10.1200/jco.2025.43.16_suppl.e13514.Peer-Reviewed Original ResearchEarly phase clinical trialsOverall survivalPerformance statusAnalyze factors associated with overall survivalFactors associated with overall survivalClinical trialsDose of study therapyDistance to treatment centerUnivariate Cox proportional hazards modelSolid tumor patientsECOG performance statusRetrospective chart reviewEffective novel therapiesPhase clinical trialsCox proportional hazards modelsProportional hazards modelAssociated with decreased likelihoodNon-white raceMedian OSECOG PSStudy therapyT patientsOncology clinical trialsMedian timeTherapeutic optionsEnhancing prognostic accuracy in lung cancer brain metastases through histopathologic feature integration and AI-based image analysis.
Breuer G, Sritharan D, Chadha S, Hager T, Fu D, Aneja S. Enhancing prognostic accuracy in lung cancer brain metastases through histopathologic feature integration and AI-based image analysis. Journal Of Clinical Oncology 2025, 43: e13608-e13608. DOI: 10.1200/jco.2025.43.16_suppl.e13608.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesCox proportional hazards modelsClinical featuresHistopathological featuresProportional hazards modelLung adenocarcinoma metastasisWhole slide imagesBrain metastasesAdenocarcinoma metastasisManagement of brain metastasesLung cancer brain metastasisBrain metastasis diagnosisCancer brain metastasesHazards modelEstimate overall survivalSystemic disease controlOverall survival estimatesGround-truth labelsAttention-based modelAttention-based networkMetastasis biopsiesSlide imagesNeural network-based modelOverall survivalAI-based image analysisAmbient air pollution in critical windows of exposure and spontaneous miscarriage in a preconception cohort
Jukic A, Konrad K, Buller I, Jahnke J, Rosen Vollmar A, McConnaughey D, Keil A, Steiner A. Ambient air pollution in critical windows of exposure and spontaneous miscarriage in a preconception cohort. Environmental Research 2025, 281: 121965. PMID: 40447021, DOI: 10.1016/j.envres.2025.121965.Peer-Reviewed Original ResearchConceptsAir pollutionExposure to PM<sub>10</sub>Increased air pollution exposureAir pollution risksAmbient air pollutionAir pollution exposureConfidence intervalsInterquartile range increaseCritical windows of exposureLow vitamin DSelf-reported pregnancy lossChemical transport modelHazard ratioQuantile-based g-computationWindows of exposurePollutant concentrationsPollution riskProspective time-to-pregnancy studyMiscarriage riskPollution exposureAssociated with small increasesRange increaseCox proportional hazards modelsPollutionPublic health implicationsRisk of unprovoked seizures after discontinuation of antiseizure medication at discharge following acute symptomatic seizures
Punia V, Byrnes M, Thompson N, Ayub N, Rubinos C, Zafar S, Sivaraju A, investigators F. Risk of unprovoked seizures after discontinuation of antiseizure medication at discharge following acute symptomatic seizures. Epilepsia 2025 PMID: 40387211, DOI: 10.1111/epi.18464.Peer-Reviewed Original ResearchAcute symptomatic seizuresAntiseizure medicationsUnprovoked seizuresRisk of unprovoked seizuresSymptomatic seizuresAssociated with electrographic seizuresMedian follow-upRetrospective cohort studyCox proportional hazards modelsCause-specific Cox proportional hazards modelsProportional hazards modelIncidence of unprovoked seizuresASyS patientsConsecutive adultsSingle-centerElectrographic seizuresNo significant differenceCumulative incidenceFollow-upCohort studyPatient populationFunctional outcomesSeizure riskPatientsHospital dischargeDeclining Serum Albumin with Stable BMI: A Mortality Indicator in Pre- Dialysis CKD
Sarav M, Shrestha P, Naseer A, Thomas F, Sumida K, Kalantar-Zadeh K, Kovesdy C. Declining Serum Albumin with Stable BMI: A Mortality Indicator in Pre- Dialysis CKD. Journal Of Renal Nutrition 2025 PMID: 40339729, DOI: 10.1053/j.jrn.2025.04.005.Peer-Reviewed Original ResearchStable body mass indexAdvanced chronic kidney diseaseBody mass indexChronic kidney diseaseCohort of US veteransPre-dialysis chronic kidney diseasePredialysis chronic kidney diseaseClinically relevant declineChronic kidney disease managementComprehensive nutritional assessmentSerum albumin levelAfrican American participantsProportion of patientsDialysis chronic kidney diseaseCox proportional hazards modelsKidney replacement therapySerum albumin measurementProportional hazards modelMortality indicatorsPredialysis periodUS veteransReplacement therapyAlbumin levelsNutritional markersNationwide cohortInvestigation on the factors associated with maintenance of paliperidone long-acting injection in the real-world treatment of patients with schizophrenia
Kang N, Jo A, Joo S, Lee J, Lee K, Kim Y, Jeong J, Lee J, Lee J, Kim H. Investigation on the factors associated with maintenance of paliperidone long-acting injection in the real-world treatment of patients with schizophrenia. Therapeutic Advances In Psychopharmacology 2025, 15: 20451253251333987. PMID: 40296870, PMCID: PMC12035106, DOI: 10.1177/20451253251333987.Peer-Reviewed Original ResearchPaliperidone LAIPaliperidone long-acting injectionLong-acting injectionDiscontinuation ratesRisk of treatment discontinuationClozapine useLong-term treatment continuationEarly phase of treatmentSchizophrenia treatmentAugmentation agentsConcurrent antipsychoticsPhase of treatmentAntipsychoticsSchizophreniaMultivariate Cox proportional hazards modelLong-actingKaplan-Meier survival analysisStandard dosing regimenRisk of discontinuationBaseline clinical factorsTreatment of patientsRetrospective observational studyYear of treatmentCox proportional hazards modelsReal-world treatmentManagement and Outcomes in Confirmed or Suspected Acute Symptomatic Seizure: Role of Structured Outpatient Care
Punia V, Byrnes M, Thompson N, Ayub N, Rubinos C, Zafar S, Sivaraju A, Ying Z, Fesler J, Hantus S, investigators P. Management and Outcomes in Confirmed or Suspected Acute Symptomatic Seizure: Role of Structured Outpatient Care. Annals Of Clinical And Translational Neurology 2025, 12: 1225-1239. PMID: 40244869, PMCID: PMC12172096, DOI: 10.1002/acn3.70039.Peer-Reviewed Original ResearchConceptsAcute symptomatic seizuresSymptomatic seizuresUnprovoked seizuresASyS patientsEpileptiform abnormalitiesMedian 14-month follow-upContinuous EEGRetrospective study of adultsCox proportional hazards modelsCause-specific Cox proportional hazards modelsProportional hazards modelRisk of unprovoked seizuresOutpatient EEGAlive patientsStudy of adultsOutpatient careSingle-centerRetrospective studyFollow-upPatientsCumulative incidence functionHazards modelSeizuresPost-discharge managementAbnormalitiesImmune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction
Chen Y, Dolladille C, Rao A, Palaskas N, Deswal A, Lehmann L, Cautela J, Courand P, Hayek S, Zhu H, Cheng R, Alexandre J, Baldassarre L, Roubille F, Laufer-Perl M, Asnani A, Ederhy S, Tamura Y, Francis S, Gaughan E, Johnson D, Flint D, Rainer P, Bailly G, Ewer S, Aras M, Arangalage D, Cariou E, Florido R, Peretto G, Zadok O, Akhter N, Narezkina A, Levenson J, Liu Y, Crusz S, Issa N, Piriou N, Leong D, Sandhu S, Turker I, Moliner P, Obeid M, Heinzerling L, Chang W, Stewart A, Venkatesh V, Du Z, Yadavalli A, Kim D, Chandra A, Zhang K, Power J, Moslehi J, Salem J, Zaha V, Registry I. Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction. JACC CardioOncology 2025, 7: 234-248. PMID: 40246381, PMCID: PMC12046861, DOI: 10.1016/j.jaccao.2025.01.020.Peer-Reviewed Original ResearchLeft ventricular ejection fractionImmune checkpoint inhibitorsPredictors of left ventricular ejection fractionAll-cause mortalityHeart failureAssociated with 30-day all-cause mortalityDocumented LVEFAssociated with left ventricular ejection fractionReduced left ventricular ejection fractionImmune checkpoint inhibitor initiationImmune checkpoint inhibitor myocarditisHistory of heart failurePre-existing heart failureTransforming cancer treatmentVentricular ejection fractionCox proportional hazards modelsBody mass indexMultivariate logistic regressionTime of hospitalizationProportional hazards modelCheckpoint inhibitorsMyositis symptomsChest radiationCardiotoxic therapiesEjection fraction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply